ESMO minimum clinical recommendations for the diagnosis, treatment and follow-up of chronic myelogenous leukemia (CML)

Annals of Oncology

Volumn 16, Issue SUPPL. 1, 2005, Pages

  Simonsson, B ^a,d   Kloke, O ^b,d   Stahel, R A ^c,d  

^a UPPSALA UNIVERSITY HOSPITAL   (Sweden)

^b Elisabeth Krankenhaus GmbH   (Germany)

^c UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^d ESMO Guidelines Task Force   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; CYTARABINE; HYDROXYUREA; IMATINIB;

ALLOGENEIC STEM CELL TRANSPLANTATION; ARTICLE; CANCER INCIDENCE; CANCER MORTALITY; CANCER REGRESSION; CANCER RISK; CANCER STAGING; CHRONIC MYELOID LEUKEMIA; CLINICAL FEATURE; DRUG DOSE REGIMEN; DRUG EFFICACY; FOLLOW UP; HUMAN; LABORATORY DIAGNOSIS; PHILADELPHIA 1 CHROMOSOME; PRIORITY JOURNAL; PROGNOSIS; RISK ASSESSMENT; RISK FACTOR; TREATMENT PLANNING;

EID: 21044454073     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1093/annonc/mdi807     Document Type: Article

References (6)

1. Sokal JE, Cox EB, Baccarani M et al. Prognostic discrimination in "good risk" chronic granulocytic leukaemia. Blood 1984; 63: 789-799.
2. Hasford J, Pfirrman M, Hehlmann R et al. A new prognostic score for survival of patients with chronic myeloid leukaemia treated with interferon alfa. J Natl Cancer Inst 1998; 90: 850-858.
3. Silver RT, Woolf SH, Hehlmann R et al. An evidence-based analysis of the effect of Busulfan, Hydroxyurea, Interferon and allogeneic bone marrow transplantation in treating the chronic phase of chronic myeloid leukaemia: Developed for the American Society of Hematology. Blood 1999; 94: 1517-1536.
4. Enright H, McGlave P. Chronic myelogenous leukaemia. In Hoffman R, Benz EJ, Shattil SJ (eds): Hematology: Basic Principles and Practice. Philadelphia: Churchill Livingstone 2000.
5. Kolb HJ, Mittermuller J, Clemm C et al. Donor leukocyte transfusions for treatment of recurrent chronic myelogenous leukaemia in marrow transplant patients. Blood 1990; 76: 2462-2465.
6. O'Brien SG, Guilhot F, Larson RA et al. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 2003; 348: 994-1004.